Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

VEGF-A/VEGFR Inhibition Restores Hematopoietic Homeostasis in the Bone Marrow and Attenuates Tumor Growth.

O'Donnell RK, Falcon B, Hanson J, Goldstein WE, Perruzzi C, Rafii S, Aird WC, Benjamin LE.

Cancer Res. 2016 Feb 1;76(3):517-24. doi: 10.1158/0008-5472.CAN-14-3023. Epub 2015 Dec 30.

2.

Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth.

Phung TL, Du W, Xue Q, Ayyaswamy S, Gerald D, Antonello Z, Nhek S, Perruzzi CA, Acevedo I, Ramanna-Valmiki R, Rodriguez-Waitkus P, Enayati L, Hochman ML, Lev D, Geeganage S, Benjamin LE.

Cancer Res. 2015 Jan 1;75(1):40-50. doi: 10.1158/0008-5472.CAN-13-2961. Epub 2014 Nov 11.

3.

RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription.

Gerald D, Adini I, Shechter S, Perruzzi C, Varnau J, Hopkins B, Kazerounian S, Kurschat P, Blachon S, Khedkar S, Bagchi M, Sherris D, Prendergast GC, Klagsbrun M, Stuhlmann H, Rigby AC, Nagy JA, Benjamin LE.

Nat Commun. 2013;4:2824. doi: 10.1038/ncomms3824.

4.

Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.

Du W, Gerald D, Perruzzi CA, Rodriguez-Waitkus P, Enayati L, Krishnan B, Edmonds J, Hochman ML, Lev DC, Phung TL.

Lab Invest. 2013 Oct;93(10):1115-27. doi: 10.1038/labinvest.2013.98. Epub 2013 Aug 12.

5.

Correction: Overexpression of MyrAkt1 in Endothelial Cells Leads to Erythropoietin- and BMP4-Independent Splenic Erythropoiesis in Mice.

O'Donnell RK, Goldstein WE, Perruzzi C, Benjamin LE, Aird WC.

PLoS One. 2013 Jun 18;8(6). doi: 10.1371/annotation/207f3e91-451e-4508-afab-77f01dae3fe9. Print 2013.

6.

Overexpression of MyrAkt1 in endothelial cells leads to erythropoietin- and BMP4-independent splenic erythropoiesis in mice.

O'Donnell RK, Goldstein WE, Perruzzi C, Benjamin LE, Aird WC.

PLoS One. 2013;8(1):e55095. doi: 10.1371/journal.pone.0055095. Epub 2013 Jan 28. Erratum in: PLoS One. 2013 Jun 18;8(6):null. Aird, William [corrected to Aird, William C].

7.

RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.

Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE.

Cancer Res. 2013 Jan 1;73(1):50-61. doi: 10.1158/0008-5472.CAN-11-3055. Epub 2012 Nov 7.

8.

Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.

Kazerounian S, Duquette M, Reyes MA, Lawler JT, Song K, Perruzzi C, Primo L, Khosravi-Far R, Bussolino F, Rabinovitz I, Lawler J.

Blood. 2011 Apr 28;117(17):4658-66. doi: 10.1182/blood-2010-09-305284. Epub 2011 Mar 4.

9.

Akt promotes endocardial-mesenchyme transition.

Meadows KN, Iyer S, Stevens MV, Wang D, Shechter S, Perruzzi C, Camenisch TD, Benjamin LE.

J Angiogenes Res. 2009 Sep 21;1:2. doi: 10.1186/2040-2384-1-2.

10.

Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.

Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J.

FASEB J. 2009 Oct;23(10):3368-76. doi: 10.1096/fj.09-131649. Epub 2009 Jun 15.

11.

Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina.

Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, Swerlick R, Bornstein P, Lawler J, Benjamin LE.

Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1344-51. doi: 10.1152/ajpheart.01246.2008. Epub 2009 Mar 20.

12.

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.

Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE.

Cancer Res. 2008 Nov 15;68(22):9551-7. doi: 10.1158/0008-5472.CAN-08-2058.

13.

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE.

Cancer Cell. 2006 Aug;10(2):159-70.

14.
15.

Functional overlap and cooperativity among alphav and beta1 integrin subfamilies during skin angiogenesis.

Perruzzi CA, de Fougerolles AR, Koteliansky VE, Whelan MC, Westlin WF, Senger DR.

J Invest Dermatol. 2003 Jun;120(6):1100-9.

16.

Molecular profiling of angiogenesis markers.

Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR.

Am J Pathol. 2002 Jul;161(1):35-41.

17.
18.

Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity.

Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8. Epub 2001 May 1.

19.

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.

Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR.

Nat Med. 1999 Dec;5(12):1390-5.

PMID:
10581081
20.

Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins.

Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M.

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13612-7.

21.

Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.

Senger DR, Perruzzi CA.

Biochim Biophys Acta. 1996 Nov 8;1314(1-2):13-24.

22.

Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion.

Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L.

Ann N Y Acad Sci. 1995 Apr 21;760:83-100. No abstract available.

PMID:
7540380
23.

Osteopontin expression and distribution in human carcinomas.

Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR.

Am J Pathol. 1994 Sep;145(3):610-23.

24.
25.

Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces.

Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR.

Mol Biol Cell. 1992 Oct;3(10):1169-80.

26.

Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.

Senger DR, Perruzzi CA, Papadopoulos A.

Anticancer Res. 1989 Sep-Oct;9(5):1291-9. Review.

PMID:
2686530
27.

Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin.

Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG.

Biochim Biophys Acta. 1989 Jun 13;996(1-2):43-8.

PMID:
2736258
28.

Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation.

Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG.

Cancer Res. 1988 Oct 15;48(20):5770-4.

30.

A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Senger DR, Perruzzi CA, Feder J, Dvorak HF.

Cancer Res. 1986 Nov;46(11):5629-32.

31.
32.

A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells.

Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF.

Nature. 1983 Apr 21;302(5910):714-5.

PMID:
6835406
33.

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF.

Science. 1983 Feb 25;219(4587):983-5.

PMID:
6823562

Supplemental Content

Loading ...
Support Center